OrthoPediatrics Stock (NASDAQ:KIDS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$17.83

52W Range

$14.42 - $23.70

50D Avg

$17.06

200D Avg

$17.66

Market Cap

$457.71M

Avg Vol (3M)

$164.37K

Beta

1.01

Div Yield

-

KIDS Company Profile


OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

562

IPO Date

Oct 13, 2017

Website

KIDS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Sports Medicine And Other$4.00M--
Trauma and Deformity$166.30M$145.13M$106.78M
Spine$66.05M$55.15M$37.93M
ACL Reconstruction and Other-$4.45M$4.02M

Fiscal year ends in Dec 25 | Currency in USD

KIDS Financial Summary


Dec 25Dec 24Dec 23
Revenue$236.35M$204.73M$148.73M
Operating Income$-29.00M$-29.52M$-26.75M
Net Income$-39.65M$-37.82M$-20.97M
EBITDA$-7.88M$-10.44M$-8.38M
Basic EPS$-1.69$-1.64$-0.92
Diluted EPS$-1.69$-1.64$-0.92

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26Apr 30, 26 | 12:00 AM
Q4 25Feb 26, 26 | 4:30 PM
Q3 25Oct 28, 25 | 4:30 PM

Peer Comparison


TickerCompany
TMCITreace Medical Concepts, Inc.
SMLRSemler Scientific, Inc.
CBLLCeriBell, Inc.
BVSBioventus Inc.
EOLSEvolus, Inc.
RXSTRxSight, Inc.
SRDXSurmodics, Inc.
TOIThe Oncology Institute, Inc.
LABStandard BioTools Inc.
EHABEnhabit, Inc.